The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Self-Supplied Tumor Oxygenation through Separated Liposomal Delivery of H2O2 and Catalase for Enhanced Radio-Immunotherapy of Cancer
Abstract
The recent years have witnessed the blooming of cancer immunotherapy, as well as their combinational use together with other existing cancer treatment techniques including radiotherapy. However, hypoxia is one of several causes of the immunosuppressive tumor microenvironment (TME). Herein, we develop an innovative strategy to relieve tumor hypoxia by delivering exogenous H 2 O 2 into tumors and the subsequent catalase-triggered H 2 O 2 decomposition. In our experiment, H 2 O 2 and catalase are separately loaded within stealthy liposomes. After intravenous (iv) preinjection of CAT@liposome, another dose of H 2 O 2 @liposome is injected 4 h later. The sustainably released H 2 O 2 could be decomposed by CAT@liposome, resulting in a long lasting effect in tumor oxygenation enhancement. As the result, the combination treatment by CAT@liposome plus H 2 O 2 @liposome offers remarkably enhanced therapeutic effects in cancer radiotherapy as observed in a mouse tumor model as well as a more clinically relevant patient-derived xenograft tumor model. Moreover, the relieved tumor hypoxia would reverse the immunosuppressive TME to favor antitumor immunities, further enhancing the combined radio-immunotherapy with cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade. This work presents a simple yet effective strategy to promote tumor oxygenation via sequential delivering catalase and exogenous H 2 O 2 into tumors using well-established liposomal carriers, showing great potential for clinical translation in radio-immunotherapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401
Cited by
Fu, L., Wan, Y., Qi, C., He, J., Li, C., Yang, C., Xu, H., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202006892 · Cited by 820
Glucose Oxidase‐Instructed Multimodal Synergistic Cancer Therapy
Fu, L., Qi, C., Hu, Y., Lin, J., & Huang, P. (2019) · Advanced Materials · doi:10.1002/adma.201808325 · Cited by 600
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 494
Zhou, Y., Fan, S., Feng, L., Huang, X., & Chen, X. (2021) · Advanced Materials · doi:10.1002/adma.202104223 · Cited by 463
Liang, S., Deng, X., Chang, Y., Sun, C., Shao, S., Xie, Z., Xiao, X., Ma, P., Zhang, H., Cheng, Z., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01595 · Cited by 436
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Tailoring Materials for Modulation of Macrophage Fate
Li, J., Jiang, X., Li, H., Gelinsky, M., & Gu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202004172 · Cited by 403
X-ray-activated nanosystems for theranostic applications
Chen, X., Song, J., Chen, X., & Yang, H. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00921j · Cited by 401
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Liang, S., Deng, X., Xu, G., Xiao, X., Wang, M., Guo, X., Ma, P., Cheng, Z., Zhang, D., & Lin, J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201908598 · Cited by 324
Recent advances in enhanced chemodynamic therapy strategies
Tian, Q., Xue, F., Wang, Y., Cheng, Y., An, L., Yang, S., Chen, X., & Huang, G. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101162 · Cited by 290
Yin, S., Song, G., Yang, Y., Zhao, Y., Wang, P., Zhu, L., Yin, X., & Zhang, X. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201901417 · Cited by 279
He, L., Ni, Q., Mu, J., Fan, W., Liu, L., Wang, Z., Li, L., Tang, W., Liu, Y., Cheng, Y., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c02497 · Cited by 278
Jiang, W., Zhang, Z., Wang, Q., Dou, J., Zhao, Y., Ma, Y., Liu, H., Xu, H., & Wang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01458 · Cited by 146
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Nanomaterials Based on Functional Polymers for Sensitizing Cancer Radiotherapy
Lin, J., Yin, M., Liu, X., Meng, F., & Luo, L. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202200194 · Cited by 18
Metadata
- Authors
- Song, X., Xu, J., Liang, C., Chao, Y., Jin, Q., Wang, C., Chen, M., & Liu, Z.
- Venue
- Nano Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-09-24
- Volume
- 18
- Issue
- 10
- Pages
- 6360-6368
- ISSN
- 1530-6984 (ISSN-L)
- 1530-6992
- OpenAlex
- W2893436613
- Cited by
- 298
- References
- 49
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.